PCR 2009 SPIRIT V 1-Year Results

The 1 year clinical results of the SPIRIT V Single Arm Registry show that the use of the XIENCE V stent in an all-comer population has low TLR and Stent Thrombosis rates out to 1 year.

With a low cumulative 0.66% Stent Thrombosis rate and a 5.1% MACE rate at one year,* XIENCE V demonstrates impressive results in real-world patients, consistent with its superior performance in two large randomized SPIRIT trials.

¹Hierarchical MACE = cardiac death. MI attributed to the target vessel and TLR.

Complex Lesions in a Real-World Population of 2,663 patients

XIENCE V demonstrates low event rates.

Baseline Patient and Lesion Characteristics Across SPIRIT V

Growing SPIRIT Body of Data

Find out more about SPIRIT V 1-Year Results

* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.

AP2931126 Rev. A

Site Map | International Terms of Use | International Privacy Policy | Contact Us

All illustrations are artist’s renditions.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.